A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Naturland Holding Zrt's Debt-to-EBITDA or its related term are showing as below:
BUD:NATURLAND'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.09 Med: 0.17 Max: 0.31
Current: 0.09
During the past 5 years, the highest Debt-to-EBITDA Ratio of Naturland Holding Zrt was 0.31. The lowest was 0.09. And the median was 0.17.
BUD:NATURLAND's Debt-to-EBITDA is ranked better than 87.19% of 687
companies
in the Drug Manufacturers industry
Industry Median: 1.66
vs BUD:NATURLAND: 0.09
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Naturland Holding Zrt Debt-to-EBITDA Related Terms
Naturland Holding Zrt Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Naturland Holding Zrt's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUD:NATURLAND vs ZTS, UTHR, VTRS: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Naturland Holding Zrt's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Naturland Holding Zrt Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Naturland Holding Zrt's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Naturland Holding Zrt's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2025) EBITDA data.
Naturland Holding Zrt (BUD:NATURLAND) has a Debt-to-EBITDA of 0.09 as of Jun. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Naturland Holding Zrt. This is 47% below median its historical median of 0.17. Over the past decade, Naturland Holding Zrt's Debt-to-EBITDA has ranged from 0.09 to 0.31. According to the industry distribution chart, Naturland Holding Zrt ranks #88 out of 687 companies in the Drug Manufacturers industry, placing it in the top 12.8%.
Is Naturland Holding Zrt's Debt-to-EBITDA too high?
Naturland Holding Zrt's current Debt-to-EBITDA of 0.09 is 47% below median its 10-year median of 0.17. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 0.31. The Drug Manufacturers industry median Debt-to-EBITDA is 1.66. Naturland Holding Zrt's value of 0.09 is 94.6% below this industry median. Based on the distribution chart, Naturland Holding Zrt ranks #88 out of 687 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Naturland Holding Zrt has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Naturland Holding Zrt's Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Naturland Holding Zrt ranks #88 out of 687 companies for Debt-to-EBITDA. This places Naturland Holding Zrt in the top 13% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.66. Naturland Holding Zrt's value of 0.09 is 94.6% below this benchmark. Historically, Naturland Holding Zrt's own Debt-to-EBITDA has ranged from 0.09 to 0.31 over the past decade. While the company's 10-year median is 0.17 vs. the industry median of 1.66, Naturland Holding Zrt has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.66, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Naturland Holding Zrt's current Debt-to-EBITDA of 0.09 is 94.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Naturland Holding Zrt. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Naturland Holding Zrt's current Debt-to-EBITDA is 0.09, which is 47% below median its own 10-year median of 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturland Holding Zrt stock overvalued right now?
Based on GuruFocus' analysis, Naturland Holding Zrt (BUD:NATURLAND) is currently considered Fairly Valued. The stock's GF Value™ is Ft2,887.31, compared to a current price of Ft2,760.00 — trading 4.4% below its estimated fair value. The current Debt-to-EBITDA is 0.09, which is 47% below median its 10-year median of 0.17 and 94.6% below the Drug Manufacturers industry median of 1.66. Naturland Holding Zrt's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Naturland Holding Zrt (BUD:NATURLAND), the current Debt-to-EBITDA is 0.09 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Naturland Holding Zrt (BUD:NATURLAND) Overvalued in 2026?
Based on GuruFocus' analysis, Naturland Holding Zrt stock appears to be undervalued.
The current stock price of Ft2,760.00 is trading 4.4% below its estimated GF Value™ of Ft2,887.31.
GuruFocus considers Naturland Holding Zrt to be Fairly Valued.
Key valuation signals for BUD:NATURLAND:
Debt-to-EBITDA: 0.09 (47% below median its 10-year median of 0.17)
GF Value™: Ft2,887.31 vs. price of Ft2,760.00 (4.4% below fair value)
Industry Position: 94.6% below the Drug Manufacturers median (#88 of 687)
No single metric tells the full story. See the BUD:NATURLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Naturland Holding Zrt thro9ugh its subsidiaries engage in the production of pharmaceutical products. It engages in the development, production, and wholesale of dietary supplements and cosmetics, herbal medicine, teas, and essential oils. The firm offers tablets, suppositories, ointments, and ophthalmic base solutions.
61GF Score
Get the complete analysis for BUD:NATURLAND
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NATURLAND has been successfully added to your 
